Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

New rapid laboratory test successful in identifying GBS colonization in pregnant women

A more rapid laboratory test for pregnant women to detect potentially deadly Group B strep (GBS) has been successful at identifying GBS colonization in six and a half hours, according to the results of a study from The University of Texas Health Science Center at Houston (UTHealth).

11 Mar 2013

Novel drug seems to increase effectiveness of usual chemotherapy against IBC

Researchers in the University of Delaware's Department of Biological Sciences are investigating a new drug that has shown positive results in early tests of its ability to fight a rare and aggressive form of breast cancer.

8 Mar 2013

Antibiotic prophylaxis after IVT may be harmful

Researchers are warning against routine antibiotic prophylaxis with intravitreal injection after finding that the practice can increase the antibiotic resistance of ocular surface flora.

6 Mar 2013

Nursing home patients with pneumonia may need viral screening

Viral testing should be carried out among all older individuals who have been admitted to hospital for nursing home-acquired pneumonia, recommend researchers.

5 Mar 2013

Overall risk of infection associated with most neuroangiographic procedures is very low

Patients undergoing cerebral angiography and neurointerventional procedures on the brain are at very low risk of infection-even without preventive antibiotics, reports a study in the March issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

5 Mar 2013

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Amoxicillin is a broad spectrum penicillin, and in the UK is one of the most frequently used antibiotics. It is commonly used either on its own or, where there are particular concerns about resistance, in combination as Co-amoxiclav (as Amoxicillin-clavulanic acid) which extends its anti-bacterial spectrum.

1 Mar 2013

Scientists take important step toward designing a uniform protocol for microbiome research

Earth Day may be more than a month away, but another, more personal, ecosystem has been shown to also be worth protecting-within our bodies are communities of microbes that affect the behavior of human cells hosting them.

1 Mar 2013

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).

1 Mar 2013

Researchers develop new genetically altered mice that model earliest stages of Alzheimer's

Researchers at the University of Florida and The Johns Hopkins University have developed a line of genetically altered mice that model the earliest stages of Alzheimer's disease. This model may help scientists identify new therapies to provide relief to patients who are beginning to experience symptoms.

1 Mar 2013

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Anacor Pharmaceuticals today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302).

28 Feb 2013

Reintroducing normal microbial diversity can eliminate VRE from intestinal tracts

Too much antibiotic can decimate the normal intestinal microbiota, which may never recover its former diversity. That, in turn, renders the GI tract vulnerable to being colonized by pathogens. Now researchers from Memorial Sloan-Kettering Cancer Center, New York, NY, and Centro Superior de Investigaci-n en Salud P-blica, Valencia, Spain, show that reintroducing normal microbial diversity largely eliminated vancomycin-resistant enterococci (VRE) from the intestinal tracts of mice..

28 Feb 2013

Faecal microbiota transplantation highly effective in treating recurrent C. difficile infections

Clostridium difficile infections have developed into a virtual pandemic over the past two decades. The outcome of standard antibiotic treatment is unsatisfactory: the recurrence rates are high with every relapse increasing the risk of further follow-ups. Faecal microbiota transplantation offers a rapidly acting and highly effective alternative in treating recurrent Clostridium difficile infections (RCDI), as Professor Lawrence J. Brandt (Montefiore Medical Center, New York, USA) points out.

27 Feb 2013

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Complementary medicines include products containing herbs, vitamins, minerals, nutritional supplements, homoeopathic medicines, certain aromatherapy products and traditional Chinese medicines. For this reason they are also called herbal, natural or alternative medicines.

26 Feb 2013

New UM technology could provide five-minute diagnostic test and vaccine for Staph infections

New technology from the University of Maryland (UM) could potentially provide a five-minute diagnostic test and a vaccine for tough-to-treat Staphylococcus aureus infections, including the antibiotic-resistant MRSA, often called a "super bug," says inventor Mark Shirtliff, PhD, an associate professor at the UM School of Dentistry in Baltimore.

26 Feb 2013

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced today that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria.

26 Feb 2013

Scientists uncover atomic structure of dermcidin

An international team of scientists has discovered how an important natural antibiotic called dermcidin, produced by our skin when we sweat, is a highly efficient tool to fight tuberculosis germs and other dangerous bugs.

22 Feb 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

New bio-mimicking therapeutics could help treat skin wounds

In "before" and "after" photos from advertisements for wound-healing ointments, bandages and antibiotic creams, we see an injury transformed from an inflamed red gash to smooth and flawless skin. What we don't appreciate is the vital role that our own natural biomolecules play in the healing process, including their contribution to the growth of new cells and the development of new blood vessels that provide nutrients to those cells.

21 Feb 2013

Otolaryngology, head and neck surgery: an interview with Thomas Cherry, Cook Medical

Cook Medical is the world’s largest privately held medical device manufacturer. The ENT division is Cook’s 10th business unit/clinical division and we are excited to meet the needs of ENT patients.

From COOK MEDICAL INC. 18 Feb 2013

Researchers discover SCANR that helps protect a cell's genes against DNA interlopers

Gene wars rage inside our cells, with invading DNA regularly threatening to subvert our human blueprint. Now, building on Nobel-Prize-winning findings, UC San Francisco researchers have discovered a molecular machine that helps protect a cell's genes against these DNA interlopers.

15 Feb 2013

Antibiotic News and Research

Further Reading

New rapid laboratory test successful in identifying GBS colonization in pregnant women

Novel drug seems to increase effectiveness of usual chemotherapy against IBC

Antibiotic prophylaxis after IVT may be harmful

Nursing home patients with pneumonia may need viral screening

Overall risk of infection associated with most neuroangiographic procedures is very low

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Scientists take important step toward designing a uniform protocol for microbiome research

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Researchers develop new genetically altered mice that model earliest stages of Alzheimer's

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Reintroducing normal microbial diversity can eliminate VRE from intestinal tracts

Faecal microbiota transplantation highly effective in treating recurrent C. difficile infections

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

New UM technology could provide five-minute diagnostic test and vaccine for Staph infections

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Scientists uncover atomic structure of dermcidin

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

New bio-mimicking therapeutics could help treat skin wounds

Otolaryngology, head and neck surgery: an interview with Thomas Cherry, Cook Medical

Researchers discover SCANR that helps protect a cell's genes against DNA interlopers

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News